研究

Kakimi K, Sugie T.

Why combine and why neoadjuvant? Tumor immunological perspectives on chemoimmunotherapy in triple-negative breast cancer.

Jinushi K, Saito T, Kurose K, Suzuki S, Kojima T, Takahara T, Makino T, Ogawa T, Nishikawa H, Kakimi K, Iida S, Nakajima J, Doki Y, Oka M, Ueda R, Wada H.

Phase I study on neoadjuvant combination immunotherapy with mogamulizumab and nivolumab for solid tumors.

Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Kobayashi Y, Kakimi K, Chiba Y, Boku N, Hyodo I, Muro K.

Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer.

Kikuchi M, Takami H, Kobayashi Y, Nagaoka K, Kitagawa Y, Nomura M, Takayanagi S, Tanaka S, Saito N, Kakimi K.

Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy.

Kumagai, K., Hamada, Y., Horie, A., Shimizu, Y., Ohashi, Y., Aoki, R., Suzuki, T., Kawaguchi, K., Kuroda, A., Tsujikawa, T., Hoshi, K., & Kakimi, K.

Prognostic Implications of T Cell Receptor Repertoire Diversity in Cervical Lymph Nodes of Oral Squamous Cell Carcinoma Patients.

Nagaoka K, Nakanishi H, Tanaka H, Anindita J, Kawamura T, Tanaka T, Yamashita T, Kuroda A, Nomura S, Akita H, Itaka K, Kodama T, Kakimi K.

Neoantigen mRNA vaccines induce progenitor-exhausted T cells that support anti-PD-1 therapy in gastric cancer with peritoneal metastasis.